COVID-19 Shifts ICER Pricing Targets, Creating New Hurdles For Drug Developers

 
• By Sarah Karlin-Smith
Cost effective check approval sign concept illustration design graphic
It will be harder for drug companies to meet ICER's new COVID-19 pricing targets. • Source: Shutterstock

More from Market Access

More from Pink Sheet